TrialJournal of the National Cancer Institute2022

Tumor Cellularity and Infiltrating Lymphocytes as a Survival Surrogate in HER2-Positive Breast Cancer.

Nuria Chic et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.